Get started
Author

Jackie M. Lafky

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2013 · Evanthia Galanis, S. Keith Anderson, et al. · Clinical Cancer Research · 162
Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C.
2010 · A. Grothey, J. M. Lafky, et al. · Journal of Clinical Oncology · 13
Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745.
2011 · J. M. Hubbard, S. R. Alberts, et al. · Journal of Clinical Oncology · 3
Medical and Neuro-oncology
2011 · G. K. Prithviraj, S. R. Sommers, et al. · Neuro-Oncology · 2
PDF
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR).
2011 · S. K. Anderson, J. M. Lafky, et al. · Journal of Clinical Oncology · 2
Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
PDF
Supplementary Table 2 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
PDF
Supplementary Table 2 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
Data from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
Data from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023 · Evanthia Galanis, S. Keith Anderson, et al.
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
2011 · J. M. Lafky, B. M. Bot, et al. · Journal of Clinical Oncology
Works count: 12
Citation count: 182
H-index: 3
I10-index: 2
Year
Topic
Type